Manipulating protein acetylation in breast cancer: A promising approach in combination with hormonal therapies?

Journal of Biomedicine and Biotechnology

Volumn 2011, Issue , 2011, Pages

  Cavailles, Vincent ^a   Linares, Aurélien ^a   Dalenc, Florence ^b   Balaguer, Patrick ^a   Boulle, Nathalie ^c  

^a INSTITUT DE RECHERCHE EN CANCÉROLOGIE DE MONTPELLIER   (France)

^b Claudius Regaud Institut   (France)

^c HÔPITAL ARNAUD DE VILLENEUVE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; 6 (1,3 DIOXO 1H,3H BENZO[DE]ISOQUINOLIN 2 YL) N HYDROXYHEXANAMIDE; ANASTROZOLE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BUTYRIC ACID; CYCLOHEXIMIDE; ENTINOSTAT; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; EXEMESTANE; HC TOXIN; HISTONE DEACETYLASE; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 5; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE 8; HISTONE DEACETYLASE INHIBITOR; LETROZOLE; MESSENGER RNA; MOCETINOSTAT; PANOBINOSTAT; PROTEIN; RALOXIFENE; ROMIDEPSIN; SIRTUIN 1; TAMOXIFEN; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; TUMOR PROTEIN;

ACETYLATION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BRAIN METASTASIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL PROLIFERATION; CHROMATIN; CUTANEOUS T CELL LYMPHOMA; DEACETYLATION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG POTENCY; DRUG SAFETY; FATIGUE; GENE EXPRESSION; HODGKIN DISEASE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTRADUCTAL CARCINOMA; LYMPHOCYTOPENIA; NAUSEA; NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROGNOSIS; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN STABILITY; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; TRANSCRIPTION REGULATION; BREAST TUMOR; DRUG EFFECT; DRUG RESISTANCE; FEMALE; METABOLISM;

ACETYLATION; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HISTONE DEACETYLASE INHIBITORS; HUMANS; NEOPLASM PROTEINS; SIGNAL TRANSDUCTION;

EID: 79251547681     PISSN: 11107243     EISSN: 11107251     Source Type: Journal    
DOI: 10.1155/2011/856985     Document Type: Review

References (146)

1. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group Lancet 1998 1451 1467
2. McGuire W. L., Horwitz K. B., Pearson O. H., Segaloff A., Current status of estrogen and progesterone receptors in breast cancer Cancer 1977 39 6 2934 2947
3. Bardou V. J., Arpino G., Elledge R. M., Osborne C. K., Clark G. M., Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases Journal of Clinical Oncology 2003 21 10 1973 1979
4. Massarweh S., Schiff R., Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities Clinical Cancer Research 2007 13 7 1950 1954
5. Riggins R. B., Schrecengost R. S., Guerrero M. S., Bouton A. H., Pathways to tamoxifen resistance Cancer Letters 2007 256 1 1 24
6. Hoskins J. M., Carey L. A., McLeod H. L., CYP2D6 and tamoxifen: DNA matters in breast cancer Nature Reviews Cancer 2009 9 8 576 586
7. Heldring N., Pike A., Andersson S., Matthews J., Cheng G., Hartman J., Tujague M., Strm A., Treuter E., Warner M., Gustafsson J.., Estrogen receptors: how do they signal and what are their targets Physiological Reviews 2007 87 3 905 931
8. Yang X. J., Seto E., HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention Oncogene 2007 26 37 5310 5318
9. Yang X. J., Seto E., The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men Nature Reviews Molecular Cell Biology 2008 9 3 206 218
10. Vannini A., Volpari C., Gallinari P., Jones P., Steinkhler C., Di Marco S., Substrate binding to histone deacetylases as shown by the crystal structure of the HDAC8-substrate complex EMBO Reports 2007 8 9 879 884
11. Schuetz A., Min J., Allali-Hassani A., Schapira M., Shuen M., Loppnau P., Mazitschek R., Kwiatkowski N. P., Lewis T. A., Maglathin R. L., McLean T. H., Bochkarev A., Plotnikov A. N., Vedadi M., Arrowsmith C. H., Human HDAC7 harbors a class IIa histone deacetylase-specific zinc binding motif and cryptic deacetylase activity Journal of Biological Chemistry 2008 283 17 11355 11363
12. Ficner R., Novel structural insights into class I and II histone deacetylases Current Topics in Medicinal Chemistry 2009 9 3 235 240
13. Haberland M., Montgomery R. L., Olson E. N., The many roles of histone deacetylases in development and physiology: implications for disease and therapy Nature Reviews Genetics 2009 10 1 32 42
14. Witt O., Deubzer H. E., Milde T., Oehme I., HDAC family: what are the cancer relevant targets? Cancer Letters 2009 277 1 8 21
15. Weichert W., HDAC expression and clinical prognosis in human malignancies Cancer Letters 2009 280 2 168 176
16. Marks P. A., Breslow R., Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug Nature Biotechnology 2007 25 1 84 90
17. Tan J., Cang S., Ma Y., Petrillo R. L., Liu D., Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents Journal of Hematology and Oncology 2010 3, article no. 5
18. Cang S., Ma Y., Liu D., New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer Journal of Hematology and Oncology 2009 2, article no. 22
19. Liu T., Kuljaca S., Tee A., Marshall G. M., Histone deacetylase inhibitors: multifunctional anticancer agents Cancer Treatment Reviews 2006 32 3 157 165
20. Xu W. S., Parmigiani R. B., Marks P. A., Histone deacetylase inhibitors: molecular mechanisms of action Oncogene 2007 26 37 5541 5552
21. Bolden J. E., Peart M. J., Johnstone R. W., Anticancer activities of histone deacetylase inhibitors Nature Reviews Drug Discovery 2006 5 9 769 784
22. Minucci S., Pelicci P. G., Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer Nature Reviews Cancer 2006 6 1 38 51
23. Balasubramanian S., Verner E., Buggy J. J., Isoform-specific histone deacetylase inhibitors: the next step? Cancer Letters 2009 280 2 211 221
24. Stimson L., La Thangue N. B., Biomarkers for predicting clinical responses to HDAC inhibitors Cancer Letters 2009 280 2 177 183
25. Munster P. N., Marchion D., Thomas S., Egorin M., Minton S., Springett G., Lee J. H., Simon G., Chiappori A., Sullivan D., Daud A., Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker British Journal of Cancer 2009 101 7 1044 1050
26. Ellis L., Pan Y., Smyth G. K., George D. J., McCormack C., Williams-Truax R., Mita M., Beck J., Burris H., Ryan G., Atadja P., Butterfoss D., Dugan M., Culver K., Johnstone R. W., Prince H. M., Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma Clinical Cancer Research 2008 14 14 4500 4510
27. Khan O., Fotheringham S., Wood V., Stimson L., Zhang C., Pezzella F., Duvic M., Kerr D. J., La Thangue N. B., HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy Proceedings of the National Academy of Sciences of the United States of America 2010 107 14 6532 6537
28. Suzuki J., Chen Y. Y., Scott G. K., DeVries S., Chin K., Benz C. C., Waldman F. M., Hwang E. S., Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression Clinical Cancer Research 2009 15 9 3163 3171
29. Krusche C. A., Wulfing P., Kersting C., Vloet A., Bcker W., Kiesel L., Beier H. M., Alfer J., Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis Breast Cancer Research and Treatment 2005 90 1 15 23
30. Zhang Z., Yamashita H., Toyama T., Sugiura H., Ando Y., Mita K., Hamaguchi M., Hara Y., Kobayashi S., Iwase H., Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast Breast Cancer Research and Treatment 2005 94 1 11 16
31. Hu X., Stern H. M., Ge L., O'Brien C., Haydu L., Honchell C. D., Haverty P. M., Peters B. A., Wu T. D., Amler L. C., Chant J., Stokoe D., Lackner M. R., Cavet G., Genetic alterations and oncogenic pathways associated with breast cancer subtypes Molecular Cancer Research 2009 7 4 511 522
32. Sotiriou C., Wirapati P., Loi S., Harris A., Fox S., Smeds J., Nordgren H., Farmer P., Praz V., Haibe-Kains B., Desmedt C., Larsimont D., Cardoso F., Peterse H., Nuyten D., Buyse M., Van de Vijver M. J., Bergh J., Piccart M., Delorenzi M., Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis Journal of the National Cancer Institute 2006 98 4 262 272
33. Saal L. H., Johansson P., Holm K., Gruvberger-Saal S. K., She Q. B., Maurer M., Koujak S., Ferrando A. A., Malmstrm P., Memeo L., Isola J., Bendahl P. O., Rosen N., Hibshoosh H., Ringner M., Borg.., Parsons R., Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity Proceedings of the National Academy of Sciences of the United States of America 2007 104 18 7564 7569
34. Bild A. H., Yao G., Chang J. T., Wang Q., Potti A., Chasse D., Joshi M. B., Harpole D., Lancaster J. M., Berchuck A., Olson J. A., Marks J. R., Dressman H. K., West M., Nevins J. R., Oncogenic pathway signatures in human cancers as a guide to targeted therapies Nature 2006 439 7074 353 357
35. Chin K., DeVries S., Fridlyand J., Spellman P. T., Roydasgupta R., Kuo W. L., Lapuk A., Neve R. M., Qian Z., Ryder T., Chen F., Feiler H., Tokuyasu T., Kingsley C., Dairkee S., Meng Z., Chew K., Pinkel D., Jain A., Ljung B. M., Esserman L., Albertson D. G., Waldman F. M., Gray J. W., Genomic and transcriptional aberrations linked to breast cancer pathophysiologies Cancer Cell 2006 10 6 529 541
36. Gruvberger S., Ringner M., Chen Y., Panavally S., Saal L. H., Borg A., Fern M., Peterson C., Meltzer P. S., Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns Cancer Research 2001 61 16 5979 5984
37. Ivshina A. V., George J., Senko O., Mow B., Putti T. C., Smeds J., Lindahl T., Pawitan Y., Hall P., Nordgren H., Wong J. E. L., Liu E. T., Bergh J., Kuznetsov V. A., Miller L. D., Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer Cancer Research 2006 66 21 10292 10301
38. Minn A. J., Gupta G. P., Siegel P. M., Bos P. D., Shu W., Giri D. D., Viale A., Olshen A. B., Gerald W. L., Massagu J., Genes that mediate breast cancer metastasis to lung Nature 2005 436 7050 518 524
39. Van De Vijver M. J., He Y. D., Van 'T Veer L. J., Dai H., Hart A. A. M., Voskuil D. W., Schreiber G. J., Peterse J. L., Roberts C., Marton M. J., Parrish M., Atsma D., Witteveen A., Glas A., Delahaye L., Van Der Velde T., Bartelink H., Rodenhuis S., Rutgers E. T., Friend S. H., Bernards R., A gene-expression signature as a predictor of survival in breast cancer New England Journal of Medicine 2002 347 25 1999 2009
40. Wang Y., Klijn J. G. M., Zhang Y., Sieuwerts A. M., Look M. P., Yang F., Talantov D., Timmermans M., Meijer-Van Gelder M. E., Yu J., Jatkoe T., Berns E. M. J. J., Atkins D., Foekens J. A., Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer Lancet 2005 365 9460 671 679
41. West M., Blanchette C., Dressman H., Huang E., Ishida S., Spang R., Zuzan H., Olson J. A., Marks J. R., Nevins J. R., Predicting the clinical status of human breast cancer by using gene expression profiles Proceedings of the National Academy of Sciences of the United States of America 2001 98 20 11462 11467
42. Yu K., Ganesan K., Miller L. D., Tan P., A modular analysis of breast cancer reveals a novel low-grade molecular signature in estrogen receptor-positive tumors Clinical Cancer Research 2006 12 11 3288 3296
43. Boersma B. J., Reimers M., Yi M., Ludwig J. A., Luke B. T., Stephens R. M., Yfantis H. G., Lee D. H., Weinstein J. N., Ambs S., A stromal gene signature associated with inflammatory breast cancer International Journal of Cancer 2008 122 6 1324 1332
44. Hedenfalk I., Duggan D., Chen Y., Radmacher M., Bittner M., Simon R., Meltzer P., Gusterson B., Esteller M., Raffeld M., Yakhini Z., Ben-Dor A., Dougherty E., Kononen J., Bubendorf L., Fehrle W., Pittaluga S., Gruvberger S., Loman N., Johannsson O., Olsson H., Wilfond B., Sauter G., Kallioniemi O. P., Borg A., Trent J., Gene-expression profiles in hereditary breast cancer New England Journal of Medicine 2001 344 8 539 548
45. Lu X., Lu X., Wang Z. C., Iglehart J. D., Zhang X., Richardson A. L., Predicting features of breast cancer with gene expression patterns Breast Cancer Research and Treatment 2008 108 2 191 201
46. Perou C. M., Srile T., Eisen M. B., Van De Rijn M., Jeffrey S. S., Ress C. A., Pollack J. R., Ross D. T., Johnsen H., Akslen L. A., Fluge., Pergammenschlkov A., Williams C., Zhu S. X., Lnning P. E., Brresen-Dale A.-L., Brown P. O., Botstein D., Molecular portraits of human breast tumours Nature 2000 406 6797 747 752
47. Richardson A. L., Wang Z. C., De Nicolo A., Lu X., Brown M., Miron A., Liao X., Iglehart J. D., Livingston D. M., Ganesan S., X chromosomal abnormalities in basal-like human breast cancer Cancer Cell 2006 9 2 121 132
48. Sorlie T., Perou C. M., Tibshirani R., Aas T., Geisler S., Johnsen H., Hastie T., Eisen M. B., Van De Rijn M., Jeffrey S. S., Thorsen T., Quist H., Matese J. C., Brown P. O., Botstein D., Lnning P. E., Brresen-Dale A. L., Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proceedings of the National Academy of Sciences of the United States of America 2001 98 19 10869 10874
49. Pollack J. R., Sorlie T., Perou C. M., Rees C. A., Jeffrey S. S., Lonning P. E., Tibshirani R., Botstein D., Brresen-Dale A. L., Brown P. O., Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors Proceedings of the National Academy of Sciences of the United States of America 2002 99 20 12963 12968
50. Sorlie T., Tibshirani R., Parker J., Hastie T., Marron J. S., Nobel A., Deng S., Johnsen H., Pesich R., Geisler S., Demeter J., Perou C. M., Lnning P. E., Brown P. O., Brresen-Dale A. L., Botstein D., Repeated observation of breast tumor subtypes in independent gene expression data sets Proceedings of the National Academy of Sciences of the United States of America 2003 100 14 8418 8423
51. Desmedt C., Piette F., Loi S., Wang Y., Lallemand F., Haibe-Kains B., Viale G., Delorenzi M., Zhang Y., D'Assignies M. S., Bergh J., Lidereau R., Ellis P., Harris A. L., Klijn J. G. M., Foekens J. A., Cardoso F., Piccart M. J., Buyse M., Sotiriou C., Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series Clinical Cancer Research 2007 13 11 3207 3214
52. Ginestier C., Cervera N., Finetti P., Esteyries S., Esterni B., Adlade J., Xerri L., Viens P., Jacquemier J., Charafe-Jauffret E., Chaffanet M., Birnbaum D., Bertucci F., Prognosis and gene expression profiling of 20q13-amplified breast cancers Clinical Cancer Research 2006 12 15 4533 4544
53. Hess K. R., Anderson K., Symmans W. F., Valero V., Ibrahim N., Mejia J. A., Booser D., Theriault R. L., Buzdar A. U., Dempsey P. J., Rouzier R., Sneige N., Ross J. S., Vidaurre T., Gmez H. L., Hortobagyi G. N., Pusztai L., Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer Journal of Clinical Oncology 2006 24 26 4236 4244
54. Huang E., Cheng S. H., Dressman H., Pittman J., Tsou M. H., Horng C. F., Bild A., Iversen E. S., Liao M., Chen C. M., West M., Nevins J. R., Huang A. T., Gene expression predictors of breast cancer outcomes Lancet 2003 361 9369 1590 1596
55. Haverty P. M., Fridlyand J., Li L., Getz G., Beroukhim R., Lohr S., Wu T. D., Cavet G., Zhang Z., Chant J., High-resolution genomic and expression analyses of copy number alterations in breast tumors Genes Chromosomes and Cancer 2008 47 6 530 542
56. Julka P. K., Chacko R. T., Nag S., Parshad R., Nair A., Oh D. S., Hu Z., Koppiker C. B., Nair S., Dawar R., Dhindsa N., Miller I. D., Ma D., Lin B., Awasthy B., Perou C. M., A phase II study of sequential neoadjuvant gemcitabine plus doxorubicin followed by gemcitabine plus cisplatin in patients with operable breast cancer: prediction of response using molecular profiling British Journal of Cancer 2008 98 8 1327 1335
57. Sotiriou C., Neo S. Y., McShane L. M., Korn E. L., Long P. M., Jazaeri A., Martiat P., Fox S. B., Harris A. L., Liu E. T., Breast cancer classification and prognosis based on gene expression profiles from a population-based study Proceedings of the National Academy of Sciences of the United States of America 2003 100 18 10393 10398
58. Zhao H., Langerod A., Ji Y., Nowels K. W., Nesland J. M., Tibshirani R., Bukholm I. K., Kresen R., Botstein D., Brresen-Dale A. L., Jeffrey S. S., Different gene expression patterns in invasive lobular and ductal carcinomas of the breast Molecular Biology of the Cell 2004 15 6 2523 2536
59. Zhang Z., Yamashita H., Toyama T., Sugiura H., Omoto Y., Ando Y., Mita K., Hamaguchi M., Hayashi S. I., Iwase H., HDAC6 expression is correlated with better survival in breast cancer Clinical Cancer Research 2004 10 20 6962 6968
60. Saji S., Kawakami M., Hayashi S. I., Yoshida N., Hirose M., Horiguchi S. I., Itoh A., Funata N., Schreiber S. L., Yoshida M., Toi M., Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer Oncogene 2005 24 28 4531 4539
61. Chin S. F., Teschendorff A. E., Marioni J. C., Wang Y., Barbosa-Morais N. L., Thorne N. P., Costa J. L., Pinder S. E., Van de Wiel M. A., Green A. R., Ellis I. O., Porter P. L., Tavar S., Brenton J. D., Ylstra B., Caldas C., High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer Genome Biology 2007 8 10, article no. R215
62. Nikolsky Y., Sviridov E., Yao J., Dosymbekov D., Ustyansky V., Kaznacheev V., Dezso Z., Mulvey L., Macconaill L. E., Winckler W., Serebryiskaya T., Nikolskaya T., Polyak K., Genome-wide functional synergy between amplified and mutated genes in human breast cancer Cancer Research 2008 68 22 9532 9540
63. Inoue A., Yoshida N., Omoto Y., Oguchi S., Yamori T., Kiyama R., Hayashi S., Development of cDNA microarray for expression profiling of estrogen-responsive genes Journal of Molecular Endocrinology 2002 29 2 175 192
64. Lee Y. S., Lim K. H., Guo X., Kawaguchi Y., Gao Y., Barrientos T., Ordentlich P., Wang X. F., Counter C. M., Yao T. P., The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis Cancer Research 2008 68 18 7561 7569
65. Yoshida N., Omoto Y., Inoue A., Eguchi H., Kobayashi Y., Kurosumi M., Saji S., Suemasu K., Okazaki T., Nakachi K., Fujita T., Hayashi S. I., Prediction of prognosis of estrogen receptor-positive breast cancer with combination of selected estrogen-regulated genes Cancer Science 2004 95 6 496 502
66. Hanigan C. L., van Engeland M., De Bruine A. P., Wouters K. A., Weijenberg M. P., Eshleman J. R., Herman J. G., An inactivating mutation in HDAC2 leads to dysregulation of apoptosis mediated by APAF1 Gastroenterology 2008 135 5 1654 1664
67. Davis T., Kennedy C., Chiew Y. E., Clarke C. L., Defazio A., Histone deacetylase inhibitors decrease proliferation and modulate cell cycle gene expression in normal mammary epithelial cells Clinical Cancer Research 2000 6 11 4334 4342
68. Vigushin D. M., Ali S., Pace P. E., Mirsaidi N., Ito K., Adcock I., Coombes R. C., Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo Clinical Cancer Research 2001 7 4 971 976
69. Margueron R., Duong V., Castet A., Cavailles V., Histone deacetylase inhibition and estrogen signalling in human breast cancer cells Biochemical Pharmacology 2004 68 6 1239 1246
70. Margueron R., Licznar A., Lazennec G., Vignon F., Cavailles V., Oestrogen receptor increases p21/C gene expression and the antiproliferative activity of histone deacetylase inhibitors in human breast cancer cells Journal of Endocrinology 2003 179 1 41 53
71. Alao J. P., Stavropoulou A. V., Lam E. W. F., Coombes R. C., Vigushin D. M., Histone deacetylase inhibitor, Trichostatin A induces ubiquitin-dependent cyclin D1 degradation in MCF-7 breast cancer cells Molecular Cancer 2006 5, article no. 8
72. Ocker M., Schneider-Stock R., Histone deacetylase inhibitors: signalling towards p21cip1/waf1 International Journal of Biochemistry and Cell Biology 2007 39 7-8 1367 1374
73. Alao J. P., Lam E. W.-F., Ali S., Buluwela L., Bordogna W., Lockey P., Varshochi R., Stavropoulou A. V., Coombes R. C., Vigushin D. M., Histone deacetylase inhibitor trichostatin A represses estrogen receptor -dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines Clinical Cancer Research 2004 10 23 8094 8104
74. Duong V., Bret C., Altucci L., Mai A., Duraffourd C., Loubersac J., Harmand P. O., Bonnet S., Valente S., Maudelonde T., Cavailles V., Boulle N., Specific activity of class II histone deacetylases in human breast cancer cells Molecular Cancer Research 2008 6 12 1908 1919
75. De Los Santos M., Martinez-Iglesias O., Aranda A., Anti-estrogenic actions of histone deacetylase inhibitors in MCF-7 breast cancer cells Endocrine-Related Cancer 2007 14 4 1021 1028
76. Travaglini L., Vian L., Billi M., Grignani F., Nervi C., Epigenetic reprogramming of breast cancer cells by valproic acid occurs regardless of estrogen receptor status International Journal of Biochemistry and Cell Biology 2009 41 1 225 234
77. Fuino L., Bali P., Wittmann S., Donapaty S., Guo F., Yamaguchi H., Wang H. G., Atadja P., Bhalla K., Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B Molecular Cancer Therapeutics 2003 2 10 971 984
78. Chopin V., Toillon R. A., Jouy N., Le Bourhis X., P21 is dispensable for G1 arrest, but indispensable for apoptosis induced by sodium butyrate in MCF-7 breast cancer cells Oncogene 2004 23 1 21 29
79. Bali P., Pranpat M., Swaby R., Fiskus W., Yamaguchi H., Balasis M., Rocha K., Wang H. G., Richon V., Bhalla K., Activity of suberoylanilide hydroxamic acid against human breast cancer cells with amplification of Her-2 Clinical Cancer Research 2005 11 17 6382 6389
80. Sharma D., Blum J., Yang X., Beaulieu N., Macleod A. R., Davidson N. E., Release of methyl CpG binding proteins and histone deacetylase 1 from the estrogen receptor (ER) promoter upon reactivation in ER-negative human breast cancer cells Molecular Endocrinology 2005 19 7 1740 1751
81. Liu X. F., Bagchi M. K., Recruitment of distinct chromatin-modifying complexes by tamoxifen-complexed estrogen receptor at natural target gene promoters in vivo Journal of Biological Chemistry 2004 279 15 15050 15058
82. Biaku E., Marchion D. C., Schmitt M. L., Munster P. N., Selective inhibition of histone deacetylase 2 silences progesterone receptor-mediated signaling Cancer Research 2008 68 5 1513 1519
83. Kawai H., Li H., Avraham S., Jiang S., Avraham H. K., Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor International Journal of Cancer 2003 107 3 353 358
84. Metivier R., Penot G., Hubner M. R., Reid G., Brand H., Ko M., Gannon F., Estrogen receptor- directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter Cell 2003 115 6 751 763
85. Shang Y., Brown M., Molecular determinants for the tissue specificity of SERMs Science 2002 295 5564 2465 2468
86. Leong H., Sloan J. R., Nash P. D., Greene G. L., Recruitment of histone deacetylase 4 to the N-terminal region of estrogen receptor Molecular Endocrinology 2005 19 12 2930 2942
87. Van Rooij E., Fielitz J., Sutherland L. B., Thijssen V. L., Crijns H. J., Dimaio M. J., Shelton J., De Windt L. J., Hill J. A., Olson E. N., Myocyte enhancer factor 2 and class ii histone deacetylases control a gender-specific pathway of cardioprotection mediated by the estrogen receptor Circulation Research 2010 106 1 155 165
88. Azuma K., Urano T., Horie-Inoue K., Hayashi S. I., Sakai R., Ouchi Y., Inoue S., Association of estrogen receptor a and histone deacetylase 6 causes rapid deacetylation of tubulin in breast cancer cells Cancer Research 2009 69 7 2935 2940
89. Fiskus W., Ren Y., Mohapatra A., Bali P., Mandawat A., Rao R., Herger B., Yang Y., Atadja P., Wu J., Bhalla K., Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor- levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90 Clinical Cancer Research 2007 13 16 4882 4890
90. Malik S., Jiang S., Garee J. P., Verdin E., Lee A. V., O'Malley B. W., Zhang M., Belaguli N. S., Oesterreich S., Histone deacetylase 7 and FoxA1 in estrogen-mediated repression of RPRM Molecular and Cellular Biology 2010 30 2 399 412
91. Yao Y., Li H., Gu Y., Davidson N. E., Zhou Q., Inhibition of SIRT1 deacetylase suppresses estrogen receptor signaling Carcinogenesis 2009 31 3 382 387
92. Chopin V., Slomianny C., Hondermarck H., Le Bourhis X., Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21waf1 Experimental Cell Research 2004 298 2 560 573
93. Nakata S., Yoshida T., Horinaka M., Shiraishi T., Wakada M., Sakai T., Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells Oncogene 2004 23 37 6261 6271
94. Singh T. R., Shankar S., Srivastava R. K., HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma Oncogene 2005 24 29 4609 4623
95. Frew A. J., Lindemann R. K., Martin B. P., Clarke C. J. P., Sharkey J., Anthony D. A., Banks K. M., Haynes N. M., Gangatirkar P., Stanley K., Bolden J. E., Takeda K., Yagita H., Secrist J. P., Smyth M. J., Johnstone R. W., Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist Proceedings of the National Academy of Sciences of the United States of America 2008 105 32 11317 11322
96. Shankar S., Davis R., Singh K. P., Kurzrock R., Ross D. D., Srivastava R. K., Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice Molecular Cancer Therapeutics 2009 8 6 1596 1605
97. Hirokawa Y., Arnold M., Nakajima H., Zalcberg J., Maruta H., Signal therapy of breast cancers by the HDAC inhibitor FK228 that blocks the activation of PAK1 and abrogates the tamoxifen-resistance Cancer Biology and Therapy 2005 4 9 956 960
98. Fan J., Yin W. J., Lu J. S., Wang L., Wu J., Wu F. Y., Di G. H., Shen Z. Z., Shao Z. M., ER negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor Journal of Cancer Research and Clinical Oncology 2008 134 8 883 890
99. Palmieri D., Lockman P. R., Thomas F. C., Hua E., Herring J., Hargrave E., Johnson M., Flores N., Qian Y., Vega-Valle E., Taskar K. S., Rudraraju V., Mittapalli R. K., Gaasch J. A., Bohn K. A., Thorsheim H. R., Liewehr D. J., Davis S., Reilly J. F., Walker R., Bronder J. L., Feigenbaum L., Steinberg S. M., Camphausen K., Meltzer P. S., Richon V. M., Smith Q. R., Steeg P. S., Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks Clinical Cancer Research 2009 15 19 6148 6157
100. Margueron R., Duong V., Bonnet S., Escande A., Vignon F., Balaguer P., Cavailles V., Histone deacetylase inhibition and estrogen receptor levels modulate the transcriptional activity of partial antiestrogens Journal of Molecular Endocrinology 2004 32 2 583 594
101. DeFazio A., Chiew Y. E., Donoghue C., Lee C. S. L., Sutherland R. L., Effect of sodium butyrate on estrogen receptor and epidermal growth factor receptor gene expression in human breast cancer cell lines Journal of Biological Chemistry 1992 267 25 18008 18012
102. Reid G., Metivier R., Lin C. Y., Denger S., Ibberson D., Ivacevic T., Brand H., Benes V., Liu E. T., Gannon F., Multiple mechanisms induce transcriptional silencing of a subset of genes, including oestrogen receptor, in response to deacetylase inhibition by valproic acid and trichostatin A Oncogene 2005 24 31 4894 4907
103. Rocha W., Sanchez R., Deschenes J., Auger A., Hbert E., White J. H., Mader S., Opposite effects of histone deacetylase inhibitors on glucocorticoid and estrogen signaling in human endometrial ishikawa cells Molecular Pharmacology 2005 68 6 1852 1862
104. Kos M., Reid G., Denger S., Gannon F., Minireview: genomic organization of the human ER gene promoter region Molecular Endocrinology 2001 15 12 2057 2063
105. Pryzbylkowski P., Obajimi O., Keen J. C., Trichostatin A and 5 Aza-2′ deoxycytidine decrease estrogen receptor mRNA stability in ER positive MCF7 cells through modulation of HuR Breast Cancer Research and Treatment 2008 111 1 15 25
106. Klinge C. M., Estrogen regulation of microRNA expression Current Genomics 2009 10 3 169 183
107. Fliss A. E., Benzeno S., Rao J., Caplan A. J., Control of estrogen receptor ligand binding by Hsp90 Journal of Steroid Biochemistry and Molecular Biology 2000 72 5 223 230
108. Whitesell L., Lindquist S. L., HSP90 and the chaperoning of cancer Nature Reviews Cancer 2005 5 10 761 772
109. Yi X., Wei W., Wang S. Y., Du Z. Y., Xu Y. J., Yu X. D., Histone deacetylase inhibitor SAHA induces ER degradation in breast cancer MCF-7 cells by CHIP-mediated ubiquitin pathway and inhibits survival signaling Biochemical Pharmacology 2008 75 9 1697 1705
110. Kim S. H., Kang H. J., Na H., Lee M. O., Trichostatin A enhances acetylation as well as protein stability of ERalpha through induction of p300 protein Breast Cancer Research 2010 12 2. article no. R22
111. Yang X., Ferguson A. T., Nass S. J., Phillips D. L., Butash K. A., Wang S. M., Herman J. G., Davidson N. E., Transcriptional activation of estrogen receptor in human breast cancer cells by histone deacetylase inhibition Cancer Research 2000 60 24 6890 6894
112. Fortunati N., Bertino S., Costantino L., De Bortoli M., Compagnone A., Bandino A., Catalano M. G., Boccuzzi G., Valproic acid restores ER and antiestrogen sensitivity to ER -negative breast cancer cells Molecular and Cellular Endocrinology 2010 314 1 17 22
113. Yang X., Phillips D. L., Ferguson A. T., Nelson W. G., Herman J. G., Davidson N. E., Synergistic activation of functional estrogen receptor (ER)- by DNA methyltransferase and histone deacetylase inhibition in human ER- -negative breast cancer cells Cancer Research 2001 61 19 7025 7029
114. Keen J. C., Yan L., Mack K. M., Pettit C., Smith D., Sharma D., Davidson N. E., A novel histone deacetylase inhibitor, Scriptaid, enhances expression of functional estrogen receptor (ER) in ER negative human breast cancer cells in combination with 5-aza 2′ -deoxycytidine Breast Cancer Research and Treatment 2003 81 3 177 186
115. Macaluso M., Cinti C., Russo G., Russo A., Giordano A., pRb2/p130-E2F4/5-HDAC1-SUV39H1-p300 and pRb2/p130-E2F4/5-HDAC1-SUV39H1-DNMT1 multimolecular complexes mediate the transcription of estrogen receptor- in breast cancer Oncogene 2003 22 23 3511 3517
116. Woodfield G. W., Hitchler M. J., Chen Y., Domann F. E., Weigel R. J., Interaction of TFAP2C with the estrogen receptor- promoter is controlled by chromatin structure Clinical Cancer Research 2009 15 11 3672 3679
117. Zhou Q., Atadja P., Davidson N. E., Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation Cancer Biology and Therapy 2007 6 1 64 69
118. Zhou Q., Shaw P. G., Davidson N. E., Inhibition of histone deacetylase suppresses EGF signaling pathways by destabilizing EGFR mRNA in ER-negative human breast cancer cells Breast Cancer Research and Treatment 2009 117 2 443 451
119. Yap O. I. W. S., Bhat G., Liu L., Tollefsbol T. O., Epigenetic modifications of the estrogen receptor gene in epithelial ovarian cancer cells Anticancer Research 2009 29 1 139 144
120. Walton T. J., Li G., Seth R., McArdle S. E., Bishop M. C., Rees R. C., DNA demethylation and histone deacetylation inhibition co-operate to re-express estrogen receptor beta and induce apoptosis in prostate cancer cell-lines Prostate 2008 68 2 210 222
121. Jang E. R., Lim S. J., Lee E. S., Jeong G., Kim T. Y., Bang Y. J., Lee J. S., The histone deacetylase inhibitor trichostatin a sensitizes estrogen receptor -negative breast cancer cells to tamoxifen Oncogene 2004 23 9 1724 1736
122. Duong V., Licznar A., Margueron R., Boulle N., Busson M., Lacroix M., Katzenellenbogen B. S., Cavailles V., Lazennec G., ER and ER expression and transcriptional activity are differentially regulated by HDAC inhibitors Oncogene 2006 25 12 1799 1806
123. Faus H., Haendler B., Post-translational modifications ofsteroid receptors Biomedicine and Pharmacotherapy 2006 60 9 520 528
124. Fu M., Wang C., Reutens A. T., Wang J., Angeletti R. H., Siconolfi-Baez L., Ogryzko V., Avantaggiati M. L., Pestell R. G., p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation Journal of Biological Chemistry 2000 275 27 20853 20860
125. Jacob A. L., Lund J., Martinez P., Hedin L., Acetylation of steroidogenic factor 1 protein regulates its transcriptional activity and recruits the coactivator GCN5 Journal of Biological Chemistry 2001 276 40 37659 37664
126. Wang C., Fu M., Angeletti R. H., Siconolfi-Baez L., Reutens A. T., Albanese C., Lisanti M. P., Katzenellenbogen B. S., Kato S., Hopp T., Fuqua S. A. W., Lopez G. N., Kushner P. J., Pestell R. G., Direct acetylation of the estrogen receptor alpha hinge region by p300 regulates transactivation and hormone sensitivity Journal of Biological Chemistry 2001 276 21 18375 18383
127. Kim Y. M., Woo E. M., Chong Y. T. E., Homenko D. R., Kraus W. L., Acetylation of estrogen receptor by p300 at lysines 266 and 268 enhances the deoxyribonucleic acid binding and transactivation activities of the receptor Molecular Endocrinology 2006 20 7 1479 1493
128. Chen H., Lin R. J., Xie W., Wilpitz D., Evans R. M., Regulation of
129. Lerin C., Rodgers J. T., Kalume D. E., Kim S. H., Pandey A., Puigserver P., GCN5 acetyltransferase complex controls glucose metabolism through transcriptional repression of PGC-1 Cell Metabolism 2006 3 6 429 438
130. Vo N., Fjeld C., Goodman R. H., Acetylation of nuclear hormone receptor-interacting protein RIP140 regulates binding of the transcriptional corepressor CtBP Molecular and Cellular Biology 2001 21 18 6181 6188
131. Qiu Y., Zhao Y., Becker M., John S., Parekh B. S., Huang S., Hendarwanto A., Martinez E. D., Chen Y., Lu H., Adkins N. L., Stavreva D. A., Wiench M., Georgel P. T., Schiltz R. L., Hager G. L., HDAC1 acetylation is linked to progressive modulation of steroid receptor-induced gene transcription Molecular Cell 2006 22 5 669 679
132. Castet A., Boulahtouf A., Versini G., Bonnet S., Augereau P., Vignon F., Khockbin S., Jalaguier S., Cavaills V., Multiple domains of the receptor-interacting protein 140 contribute to transcription inhibition Nucleic Acids Research 2004 32 6 1957 1966
133. Christian M., Tullet J. M. A., Parker M. G., Characterization of four autonomous repression domains in the corepressor receptor interacting protein 140 Journal of Biological Chemistry 2004 279 15 15645 15651
134. Wei LI. N., Farooqui M., Hu X., Ligand-dependent formation of retinoid receptors, receptor-interacting protein 140 (RIP140), and histone deacetylase complex is mediated by a novel receptor-interacting motif of RIP140 Journal of Biological Chemistry 2001 276 19 16107 16112
135. Gobinet J., Carascossa S., Cavailles V., Vignon F., Nicolas J. C., Jalaguier S., SHP represses transcriptional activity via recruitment of histone deacetylases Biochemistry 2005 44 16 6312 6320
136. Kurtev V., Margueron R., Kroboth K., Ogris E., Cavailles V., Seiser C., Transcriptional regulation by the repressor of estrogen receptor activity via recruitment of histone deacetylases Journal of Biological Chemistry 2004 279 23 24834 24843
137. Li J., Wang J., Wang J., Nawaz Z., Liu J. M., Qin J., Wong J., Both corepressor proteins SMRT and N-CoR exist in large protein complexes containing HDAC3 EMBO Journal 2000 19 16 4342 4350
138. Guenther M. G., Barak O., Lazar M. A., The SMRT and N-CoR corepressors are activating cofactors for histone deacetylase 3 Molecular and Cellular Biology 2001 21 18 6091 6101
139. Li H., Rajendran G. K., Liu N., Ware C., Rubin B. P., Gu Y., SirT1 modulates the estrogen-insulin-like growth factor-1 signaling for postnatal development of mammary gland in mice Breast Cancer Research 2007 9 1, article no. R1
140. Hodges-Gallagher L., Valentine C. D., Bader S. E., Kushner P. J., Estrogen receptor beta increases the efficacy of antiestrogens by effects on apoptosis and cell cycling in breast cancer cells Breast Cancer Research and Treatment 2008 109 2 241 250
141. Rayala S. K., Talukder A. H., Balasenthil S., Tharakan R., Barnes C. J., Wang R. A., Aldaz M., Khan S., Kumar R., P21-activated kinase 1 regulation of estrogen receptor- activation involves serine 305 activation linked with serine 118 phosphorylation Cancer Research 2006 66 3 1694 1701
142. Zhou Q., Shaw P. G., Davidson N. E., Inhibition of histone deacetylase suppresses EGF signaling pathways by destabilizing EGFR mRNA in ER-negative human breast cancer cells Breast Cancer Research and Treatment 2009 117 2 443 451
143. Luu T. H., Morgan R. J., Leong L., Lim D., McNamara M., Portnow J., Frankel P., Smith D. D., Doroshow J. H., Gandara D. R., Aparicio A., Somlo G., Wong C., A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California cancer consortium study Clinical Cancer Research 2008 14 21 7138 7142
144. Lai C. J., Bao R., Tao XU., Wang J., Atoyan R., Qu H., Wang DA. G., Yin L., Samson M., Forrester J., Zifcak B., Xu G. X., DellaRocca S., Zhai H. X., Cai X., Munger W. E., Keegan M., Pepicelli C. V., Qian C., CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity Cancer Research 2010 70 9 3647 3656
145. Mahboobi S., Dove S., Sellmer A., Winkler M., Eichhorn E., Pongratz H., Ciossek T., Baer T., Maier T., Beckers T., Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of Imatinib hybrides as potent Inhibitors of wild-type and mutant BCR-ABL, PDGF-R, and histone deacetylases Journal of Medicinal Chemistry 2009 52 8 2265 2279
146. Cai X., Zhai H. X., Wang J., Forrester J., Qu H., Yin L., Lai C. J., Bao R., Qian C., Discovery of 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6- yloxy)-N- hydroxyheptanamide (CUDC-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer Journal of Medicinal Chemistry 2010 53 5 2000 2009